Supplementation of sodium butyrate protects mice from the development of non-alcoholic steatohepatitis (NASH)

British Journal of Nutrition

Volumn 114, Issue 11, 2015, Pages 1745-1755

  Jin, Cheng Jun ^a   Sellmann, Cathrin ^a   Engstler, Anna Janina ^a   Ziegenhardt, Doreen ^a   Bergheim, Ina ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Hepatic inflammation; Inducible nitric oxide synthase; Non alcoholic fatty liver disease; Reactive oxygen species; Sodium butyrate

Indexed keywords

4 HYDROXYNONENAL PROTEIN; BUTYRIC ACID; GLUCOSE; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TIGHT JUNCTION PROTEIN; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; GASTROINTESTINAL AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; TLR4 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DUODENAL TISSUE; FATTY LIVER; FEMALE; GENE EXPRESSION; GLUCOSE METABOLISM; HEPATITIS; INFLAMMATION; LIPID METABOLISM; LIPID PEROXIDATION; LIVER; LIVER INJURY; LIVER PROTECTION; LIVER WEIGHT; MACROPHAGE; MOLECULAR BIOLOGY; MOUSE; MYD88 GENE; NEUTROPHIL; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TLR 4 GENE; WEIGHT GAIN; WESTERN DIET; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DIETARY SUPPLEMENT; DUODENUM; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; INTESTINE MUCOSA; METABOLISM; NEUTROPHIL CHEMOTAXIS; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOMARKERS; BUTYRIC ACID; DIET, WESTERN; DIETARY SUPPLEMENTS; DUODENUM; FEMALE; GASTROINTESTINAL AGENTS; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; LIPID PEROXIDATION; LIVER; MICE, INBRED C57BL; NEUTROPHIL INFILTRATION; NON-ALCOHOLIC FATTY LIVER DISEASE; SIGNAL TRANSDUCTION; TIGHT JUNCTION PROTEINS; TOLL-LIKE RECEPTOR 4;

EID: 84949321362     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114515003621     Document Type: Article

References (40)

1. Sass DA, Chang P & Chopra KB (2005) Nonalcoholic fatty liver disease: A clinical review. Dig Dis Sci 50, 171-180.
2. Blachier M, Leleu H, Peck-Radosavljevic M, et al. (2013) The burden of liver disease in Europe: A review of available epidemiological data. J Hepatol 58, 593-608.
3. Leonel AJ & Alvarez-Leite JI (2012) Butyrate: implications for intestinal function. Curr Opin Clin Nutr Metab Care 15, 474-479.
4. Elamin EE, Masclee AA, Dekker J, et al. (2013) Short-chain fatty acids activate AMP-activated protein kinase and ameliorate ethanol-induced intestinal barrier dysfunction in Caco-2 cell monolayers. J Nutr 143, 1872-1881.
5. Huang XZ, Li ZR, Zhu LB, et al. (2014) Inhibition of p38 mitogen-activated protein kinase attenuates butyrateinduced intestinal barrier impairment in a Caco-2 cell monolayer model. J Pediatr Gastroenterol Nutr 59, 264-269.
6. Mattace RG, Simeoli R, Russo R, et al. (2013) Effects of sodium butyrate and its synthetic amide derivative on liver inflammation and glucose tolerance in an animal model of steatosis induced by high fat diet. PLOS ONE 8, e68626.
7. Qiao YL, Qian JM, Wang FR, et al. (2014) Butyrate protects liver against ischemia reperfusion injury by inhibiting nuclear factor kappa B activation in Kupffer cells. J Surg Res 187, 653-659.
8. Sun J, Wu Q, Sun H, et al. (2014) Inhibition of histone deacetylase by butyrate protects rat liver from ischemic reperfusion injury. Int J Mol Sci 15, 21069-21079.
9. Cresci GA, Bush K & Nagy LE (2014) Tributyrin supplementation protects mice from acute ethanol-induced gut injury. Alcohol Clin Exp Res 38, 1489-1501.
10. Spruss A, Henkel J, Kanuri G, et al. (2012) Female mice are more susceptible to nonalcoholic fatty liver disease: sex-specific regulation of the hepatic AMP-activated protein kinaseplasminogen activator inhibitor 1 cascade, but not the hepatic endotoxin response. Mol Med 18, 1346-1355.
11. Spruss A, Kanuri G, Stahl C, et al. (2012) Metformin protects against the development of fructose-induced steatosis in mice: role of the intestinal barrier function. Lab Invest 92, 1020-1032.
12. Brunt EM, Kleiner DE, Wilson LA, et al. (2011) Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 53, 810-820.
13. Bergheim I, Guo L, Davis MA, et al. (2006) Critical role of plasminogen activator inhibitor-1 in cholestatic liver injury and fibrosis. J Pharmacol Exp Ther 316, 592-600.
14. Wagnerberger S, Spruss A, Kanuri G, et al. (2012) Toll-like receptors 1-9 are elevated in livers with fructose-induced hepatic steatosis. Br J Nutr 107, 1727-1738.
15. Bergheim I (2008) Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol 48, 983-992.
16. Spruss A, Kanuri G, Wagnerberger S, et al. (2009) Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 50, 1094-1104.
17. Kanuri G, Spruss A, Wagnerberger S, et al. (2011) Role of tumor necrosis factor alpha (TNFalpha) in the onset of fructose-induced nonalcoholic fatty liver disease in mice. J Nutr Biochem 22, 527-534.
18. Landmann M, Wagnerberger S, Kanuri G, et al. (2015) Beer is less harmful for the liver than plain ethanol: studies in male mice using a binge-drinking model. Alcohol Alcohol 50, 493-500.
19. Yang F, Wang LK, Li X, et al. (2014) Sodium butyrate protects against toxin-induced acute liver failure in rats. Hepatobiliary Pancreat Dis Int 13, 309-315.
20. Spruss A, Kanuri G, Uebel K, et al. (2011) Role of the inducible nitric oxide synthase in the onset of fructose-induced steatosis in mice. Antioxid Redox Signal 14, 2121-2135.
21. Kanuri G & Bergheim I (2013) In vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD). Int J Mol Sci 14, 11963-11980.
22. Tilg H & Moschen AR (2010) Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 52, 1836-1846.
23. Machado RA, Constantino LS, Tomasi CD, et al. (2012) Sodium butyrate decreases the activation of NF-kappa B reducing inflammation and oxidative damage in the kidney of rats subjected to contrast-induced nephropathy. Nephrol Dial Transplant 27, 3136-3140.
24. Tacke F & Zimmermann HW (2014) Macrophage heterogeneity in liver injury and fibrosis. J Hepatol 60, 1090-1096.
25. Ohira H, Fujioka Y, Katagiri C, et al. (2013) Butyrate attenuates inflammation and lipolysis generated by the interaction of adipocytes and macrophages. J Atheroscler Thromb 20, 425-442.
26. Ben-Sasson SZ, Wang K, Cohen J, et al. (2013) IL-1beta strikingly enhances antigen-driven CD4 and CD8 T-cell responses. Cold Spring Harb Symp Quant Biol 78, 117-124.
27. Ben-Sasson SZ, Hogg A, Hu-Li J, et al. (2013) IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells. J ExpMed 210, 491-502.
28. Ohira H, Fujioka Y, Katagiri C, et al. (2012) Butyrate enhancement of inteleukin-1beta production via activation of oxidative stress pathways in lipopolysaccharide-stimulated THP-1 cells. J Clin Biochem Nutr 50, 59-66.
29. Maximos M, Bril F, Portillo SP, et al. (2015) The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. Hepatology 61, 153-160.
30. Gao Z, Yin J, Zhang J, et al. (2009) Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 58, 1509-1517.
31. Matis G, Kulcsar A, Turowski V, et al. (2015) Effects of oral butyrate application on insulin signaling in various tissues of chickens. Domest Anim Endocrinol 50, 26-31.
32. Kanuri G, Ladurner R, Skibovskaya J, et al. (2015) Expression of toll-like receptors 1-5 but not TLR 6-10 is elevated in livers of patients with non-alcoholic fatty liver disease. Liver Int 35, 562-568.
33. Miele L, Valenza V, La TG, et al. (2009) Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49, 1877-1887.
34. Thuy S, Ladurner R, Volynets V, et al. (2008) Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr 138, 1452-1455.
35. Wang HB, Wang PY, Wang X, et al. (2012) Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein Claudin-1 transcription. Dig Dis Sci 57, 3126-3135.
36. Ma X, Fan PX, Li LS, et al. (2012) Butyrate promotes the recovering of intestinal wound healing through its positive effect on the tight junctions. J Anim Sci 90, Suppl. 4, 266-268.
37. Volynets V, Kuper MA, Strahl S, et al. (2012) Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD). Dig Dis Sci 57, 1932-1941.
38. Liu B, Qian J, Wang Q, et al. (2014) Butyrate protects rat liver against total hepatic ischemia reperfusion injury with bowel congestion. PLOS ONE 9, e106184.
39. Endo H, Niioka M, Kobayashi N, et al. (2013) Butyrateproducing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut-liver axis. PLOS ONE 8, e63388.
40. Wang X, Sato R, Brown MS, et al. (1994) SREBP-1, a membrane-bound transcription factor released by sterolregulated proteolysis. Cell 77, 53-62.